Literature DB >> 2915166

Resistance of influenza A virus to amantadine and rimantadine: results of one decade of surveillance.

R B Belshe1, B Burk, F Newman, R L Cerruti, I S Sim.   

Abstract

All clinical isolates of influenza A viruses from patients in Huntington, West Virginia, during the decade 1978-1988 were tested, and 65 of 65 H1N1 and 176 of 181 H3N2 viruses were susceptible to the antiviral action of amantadine and rimantadine. The five resistant viruses were obtained from three members of a family undergoing therapy or prophylaxis with rimantadine. Resistant influenza emerged during treatment with rimantadine and spread to two family contacts, causing typical influenza with fever, myalgia, and cough of 5 days' or less duration. Genetic characterization of the resistant viruses when compared to the susceptible virus isolated on day 1 from the index case revealed a single amino acid change in the transmembrane portion of the M2 protein. In vitro studies showed that rimantadine was significantly more active than amantadine against both H1N1 and H3N2 viruses. Although this resistant influenza was transmitted and caused illness in one family, the absence of naturally occurring resistant viruses suggests that the emergence of new strains of influenza A each few years may prevent the widespread emergence of resistant influenza A virus.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2915166     DOI: 10.1093/infdis/159.3.430

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  42 in total

1.  Isolation of amantadine-resistant influenza a viruses (H3N2) from patients following administration of amantadine in Japan.

Authors:  J Iwahashi; K Tsuji; T Ishibashi; J Kajiwara; Y Imamura; R Mori; K Hara; T Kashiwagi; Y Ohtsu; N Hamada; H Maeda; M Toyoda; T Toyoda
Journal:  J Clin Microbiol       Date:  2001-04       Impact factor: 5.948

2.  Mapping the energy surface of transmembrane helix-helix interactions.

Authors:  J Torres; A Kukol; I T Arkin
Journal:  Biophys J       Date:  2001-11       Impact factor: 4.033

3.  Frequency of amantadine-resistant influenza A viruses during two seasons featuring cocirculation of H1N1 and H3N2.

Authors:  Reiko Saito; Takatsugu Sakai; Isamu Sato; Yasuko Sano; Hitoshi Oshitani; Mizuho Sato; Hiroshi Suzuki
Journal:  J Clin Microbiol       Date:  2003-05       Impact factor: 5.948

4.  Amantadine for influenza A.

Authors:  K G Nicholson; M J Wiselka
Journal:  BMJ       Date:  1991-02-23

5.  Bovine lactoferrin-derived peptides as novel broad-spectrum inhibitors of influenza virus.

Authors:  Maria Grazia Ammendolia; Mariangela Agamennone; Agostina Pietrantoni; Fabio Lannutti; Rosa Anna Siciliano; Beatrice De Giulio; Carla Amici; Fabiana Superti
Journal:  Pathog Glob Health       Date:  2012-03       Impact factor: 2.894

6.  Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt.

Authors:  J M Colacino; D C DeLong; J R Nelson; W A Spitzer; J Tang; F Victor; C Y Wu
Journal:  Antimicrob Agents Chemother       Date:  1990-11       Impact factor: 5.191

Review 7.  Role of combination antiviral therapy in pandemic influenza and stockpiling implications.

Authors:  Sotirios Tsiodras; John D Mooney; Angelos Hatzakis
Journal:  BMJ       Date:  2007-02-10

8.  Influenza vaccination in older patients. Immunogenicity, epidemiology and available agents.

Authors:  H Glathe; W Lange
Journal:  Drugs Aging       Date:  1995-05       Impact factor: 3.923

9.  Increasing oral absorption of polar neuraminidase inhibitors: a prodrug transporter approach applied to oseltamivir analogue.

Authors:  Deepak Gupta; Sheeba Varghese Gupta; Arik Dahan; Yasuhiro Tsume; John Hilfinger; Kyung-Dall Lee; Gordon L Amidon
Journal:  Mol Pharm       Date:  2013-01-04       Impact factor: 4.939

10.  In vitro and in vivo inhibition of ortho- and paramyxovirus infections by a new class of sulfonic acid polymers interacting with virus-cell binding and/or fusion.

Authors:  S Ikeda; J Neyts; S Verma; A Wickramasinghe; P Mohan; E De Clercq
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.